20/20 HealthCare Partners
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

19 Mar2008

INVESTMENT IN CORINDUS, INC.

Written by 2020HCP.com. Posted in News

March 19, 2008 — 20/20 HealthCare Partners LLC (Auburndale, MA) is pleased to announce that its portfolio company, Corindus, Inc., closed a B Round investment taken solely by a New York based hedge fund / private equity fund specializing in the health care industry. Corindus will use the financing to enhance its management structure, complete product development and obtain regulatory approvals in the US and Europe.

The initial funding round led by 20/20 HealthCare Partners in September 2005 enabled Corindus to progress from an early stage company through development of a sophisticated, fully functional robotic catheterization system for the CathLab.

About 20/20 HealthCare Partners LLC

20/20 HealthCare Partners LLC provides equity financing for promising growth businesses as well as for buyouts or recapitalizations of established companies specializing in the Medical Technology industry.

20/20 HealthCare Partners works with management to streamline product development, regulatory approval and market penetration. Their group of industry experienced professionals is able to introduce portfolio companies to strategic partnerships. Their relationships help expedite the product development cycle and shorten the time to market – and increase company value.

20/20HCP provides portfolio companies with tools such as active support in strategic vision, development of distribution channels, an impressive network of industry contacts, and years of industry expertise to achieve maximized growth and value leading to a potential realization.

Latest News

  • Variantyx Secures $20M Debt Financing to Support Precision Medicine in North America, Europe October 18, 2022
  • SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022
  • SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 28, 2022
  • SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022
  • SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes April 5, 2022

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact